Biohaven Pharmaceutical Holding Co. Ltd. raised $143.7 million in a public offering of common shares after the underwriters fully exercised their options.
The company issued 3,859,060 common shares at $37.25 each for the offering, including the full exercise of underwriters' option to purchase additional shares. Expected gross proceeds had been set at $125 million.
Goldman Sachs & Co. LLC and Piper Jaffray & Co. acted as joint book-running managers for the offering, with Morgan Stanley and Cantor Fitzgerald & Co. as book runners. William Blair is the co-manager of the offering.
New Haven, Conn.-based Biohaven Pharmaceutical Holding is a clinical‑stage biopharmaceutical company that develops product candidates targeting migraine and neurological diseases, including rare disorders.